- Home
- MDXH vs STRO Comparison
MDXH vs STRO Comparison
Compare MDXH & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- STRO
- Stock Information
- Founded
- MDXH 2003
- STRO 2003
- Country
- MDXH Belgium
- STRO United States
- Employees
- MDXH N/A
- STRO N/A
- Industry
- MDXH
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDXH
- STRO Health Care
- Exchange
- MDXH Nasdaq
- STRO Nasdaq
- Market Cap
- MDXH 84.6M
- STRO 77.7M
- IPO Year
- MDXH 2021
- STRO 2018
- Fundamental
- Price
- MDXH $2.30
- STRO $0.75
- Analyst Decision
- MDXH Buy
- STRO Hold
- Analyst Count
- MDXH 1
- STRO 7
- Target Price
- MDXH $6.00
- STRO $3.97
- AVG Volume (30 Days)
- MDXH 70.5K
- STRO 1.4M
- Earning Date
- MDXH 08-20-2025
- STRO 08-12-2025
- Dividend Yield
- MDXH N/A
- STRO N/A
- EPS Growth
- MDXH N/A
- STRO N/A
- EPS
- MDXH N/A
- STRO N/A
- Revenue
- MDXH $94,507,000.00
- STRO $66,434,000.00
- Revenue This Year
- MDXH $23.51
- STRO N/A
- Revenue Next Year
- MDXH $17.68
- STRO N/A
- P/E Ratio
- MDXH N/A
- STRO N/A
- Revenue Growth
- MDXH 25.46
- STRO N/A
- 52 Week Low
- MDXH $1.35
- STRO $0.52
- 52 Week High
- MDXH $3.50
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- MDXH 58.21
- STRO 38.33
- Support Level
- MDXH $1.90
- STRO $0.76
- Resistance Level
- MDXH $2.21
- STRO $0.87
- Average True Range (ATR)
- MDXH 0.12
- STRO 0.07
- MACD
- MDXH 0.00
- STRO -0.01
- Stochastic Oscillator
- MDXH 82.35
- STRO 0.00
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.